US 12,403,194 B2
Compositions for treating cancer
Kevin M. Friedman, Boston, MA (US); Molly R. Perkins, Milton, MA (US); Connor S. Dobson, Washington, DC (US); Stephen L. Sazinsky, Winchester, MA (US); Shannon G. Contrastano, Auburndale, MA (US); Emily Thompson Beura, Mansfield, MA (US); Cory Ahonen, Lebanon, NH (US); and Andrew Avery, Lebanon, NH (US)
Assigned to Kelonia Therapeutics, Inc., Boston, MA (US)
Filed by Kelonia Therapeutics, Inc., Boston, MA (US)
Filed on Oct. 17, 2024, as Appl. No. 18/919,103.
Application 18/919,103 is a continuation of application No. PCT/US2024/048301, filed on Sep. 25, 2024.
Claims priority of provisional application 63/618,878, filed on Jan. 8, 2024.
Claims priority of provisional application 63/540,336, filed on Sep. 25, 2023.
Prior Publication US 2025/0099615 A1, Mar. 27, 2025
Int. Cl. C12N 15/867 (2006.01); A61K 40/11 (2025.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/41 (2025.01); A61K 40/42 (2025.01); A61K 48/00 (2006.01); A61P 35/00 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 15/86 (2006.01)
CPC A61K 40/4215 (2025.01) [A61K 40/11 (2025.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 48/005 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 16/2809 (2013.01); C07K 16/2878 (2013.01); C12N 15/86 (2013.01); A61K 2239/13 (2023.05); C07K 2317/622 (2013.01); C12N 2740/15022 (2013.01); C12N 2740/15023 (2013.01); C12N 2740/15043 (2013.01); C12N 2830/48 (2013.01); C12N 2830/50 (2013.01)] 25 Claims
 
1. A recombinant lentiviral particle comprising:
(a) a viral envelope comprising (i) a vesicular stomatitis Indiana virus envelope glycoprotein (VSIV-G) comprising amino acid substitutions selected from the group consisting of: K47A and R354A; K47A and R354Q; K47Q and R354A; and K47Q and R354Q; and (ii) a non-viral membrane-bound tropism polypeptide comprising an anti-CD3ε scFv and a human CD8α hinge and transmembrane domain; and
(b) a recombinant lentiviral vector comprising a polynucleotide encoding a myeloproliferative sarcoma virus enhancer, negative control region deleted, d1587rev primer-binding site substituted (MND) U3 promoter or an EF1α promoter operably linked to a polynucleotide encoding a signal peptide and an anti-BCMA chimeric antigen receptor comprising an anti-BCMA scFv comprising a heavy chain variable region (VH) comprising a CDRH1, a CDRH2, and a CDRH3 comprising the amino acid sequences of SEQ ID NOs: 82, 83, and 84, and a light chain variable region (VL) comprising a CDRL1, a CDRL2, and a CDRL3 comprising the amino acid sequences of SEQ ID NOs: 86, 87, and 88; a CD8α hinge and transmembrane domain; a CD137 costimulatory domain; and a CD3ζ primary signaling domain.